Clovis Oncology Owners | StatInvestor

Health Care & Life Sciences » Biotechnology | Clovis Oncology Inc.

Clovis Oncology Inc. | Ownership

Companies that own Clovis Oncology Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Palo Alto Investors LP

4,974,007

9.44%

1,018,347

6.84%

06/30/2018

The Vanguard Group, Inc.

4,236,457

8.05%

336,348

0.01%

06/30/2018

BlackRock Fund Advisors

3,767,576

7.16%

395,342

0.01%

06/30/2018

PointState Capital LP

3,045,810

5.79%

503,687

1.28%

06/30/2018

SSgA Funds Management, Inc.

2,473,176

4.7%

400,601

0.01%

06/30/2018

Partner Fund Management LP

2,364,089

4.49%

2,364,089

1.47%

06/30/2018

OrbiMed Advisors LLC

2,330,870

4.43%

0.87%

06/30/2018

Franklin Advisers, Inc.

2,250,034

4.26%

-233,016

0.05%

06/30/2018

Redmile Group LLC

1,758,600

3.34%

1,758,600

1.95%

06/30/2018

Carmignac Gestion SA

1,521,440

2.89%

11,900

0.28%

06/30/2018

About Clovis Oncology

View Profile

Address	5500 Flatiron Parkway Boulder Colorado 80301 United States
Employees	-
Website	http://www.clovisoncology.com
Updated	07/08/2019
Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib.